PURPOSE: It is proposed that local elastase inhibition could suppress the extracellular matrix (ECM) degradation and subsequent smooth muscle cell migration and limit subsequent in-stent restenosis. This study evaluated the effect of stent-based controlled elastase inhibition on restenosis after stent implantation in a rabbit model.
ANGIOPLASTY with stent deployment has become the most common procedural intervention for cardiovascular disease, with application in as many as 70% of all percutaneous coronary interventions (1, 2) . However, in-stent restenosis, which occurs in as many as 40% of patients (3) , limits the long-term efficacy of stent implantation (4 -6) . Recent studies have suggested that in-stent restenosis is exclusively caused by intimal hyperplasia (7) consisting of smooth muscle cell (SMC) accumulation and extracellular matrix (ECM) synthesis. Although a number of growth factors and cytokines have been shown to regulate this multifactorial process, the critical regulatory role that ECM elements play in this process has recently become evident (8 -10) .
Unperturbed matrix, as present before disease, inhibits migration by maintaining SMC quiescence via specific receptor signaling (11, 12) , particularly by presenting an architectural barrier to SMCs (13) and by binding potentially mitogenic growth factors in the environment to render them unavailable to cells (14) . In contrast, the proteolytic milieu of injury leads to matrix degradation, which stimulates SMC migration, not only by disruption of physical barriers and release of bound factors, but also via breakdown products themselves (eg, matrix-derived peptides). The result can be directly chemotactic to SMCs (15) . Elastases degrade not only elastic fibers, but also fibronectin, laminin, type IV collagen, and proteoglycans in the vessel wall, and represent important contributors to postinjury proteolysis (16 -18) .
Although stents minimize angiographic evidence of luminal compromise, ECM remodeling plays a key role in plaque progression and destabilization after stent implantation. Given the important role of elastase in postinjury remodeling, we hypothesize that local stent-based elastase inhibition can suppress ECM degradation to limit subsequent plaque progression after stent implantation. In this pilot study, we employ a hybrid bioactive stent consisting of a stainless-steel stent for immediate mechanical performance and abluminal reservoirs of anchored biodegradable polymers to release a bioactive remodeling agent. In this study, we released the potent elastase inhibitor ␣-1 antitrypsin (AAT) in a rabbit model to evaluate our hypothesis.
MATERIALS AND METHODS

Microsphere Preparation and Drug Release Assay
Biodegradable microspheres composed of poly (lactic-co-glycolic-acid)-polyethylene glycol (Medisorb, Cincinnati, OH; Aldrich, Milwaukee, WI) incorporating AAT were produced with previously described techniques (19) for sustained drug release. The microspheres had a mean diameter of 10 m and a degradation time of approximately 4 weeks. AAT-containing microspheres contained 62.5 g of AAT (Calbiochem, San Diego, CA) per milligram of polymer. Blank microspheres that contained only phosphate-buffered saline solution were also prepared for a control group.
After microsphere construction, an in vitro assay was performed to confirm AAT release. One-milligram doses of AAT-containing microspheres in 1 mL phosphate-buffered saline solution (n ϭ 3 each) were incubated in a 37°C rotary bath. Sampling was performed every 24 hours until 72 hours. The samples were centrifuged at 14,000 rpm for 5 minutes, and supernatant was sampled and maintained at Ϫ20°C until the time of enzyme-linked immunosorbent assay to determine AAT concentrations in the supernatant as described previously (20) . The human-specific antibody against AAT (Dia Sorin, Stillwater, MN) was conjugated to horseradish peroxidase with use of an EZ-Link Plus Activated Peroxidase Kit (Pierce, Rockford, IL) as described by the manufacturer. All samples were tested in the same assay in duplicate.
Microsphere Loading into Channeled Stent
Stent design and MS loading were undertaken as previously described (21) . The stent is 1.6 mm in diameter with a length of 10 mm with 10 circumferentially and evenly spaced longitudinal struts. This stainless-steel stent was designed to be balloon-expandable to a maximum of 5 mm in diameter (Fig 1) . A channel with an 80-m width and 60-m depth was machined along the entire length (10 mm) of each strut of a standard Palmaz coronary stent (Cordis, Miami, FL). The stent had 10 channels and these channels covered 8.5% of the luminal area when deployed within a 4-mm vessel. Before microsphere loading, stents were pretreated to form a metal oxide-methoxysilane-monomethacrylate link, which enhances channel retention of microspheres. The microspheres were then loaded into the channels, and the space around the microspheres within each channel was filled with a rapid-release gel formulation (a 20% mixture of a 3:2 ratio of polyethylene glycol dimethacrylate and polyethylene glycol) in an attempt to prevent washout of microspheres by blood flow (Fig 2) . The stents were exposed to UV-A overnight to allow the gel to become polymerized and were then loaded on 4.0-mm ϫ 2.0-cm balloons and sterilized before use.
Stent Implantation and Tissue Harvesting
AAT microsphere-loaded stents were implanted in six rabbits (AAT group), and blank microsphereloaded stents were placed in six rabbits (control group). All animal experiments were performed in accordance with National Institutes of Health and institutional guidelines and under general anesthesia. Adult male New Zealand White rabbits weighing 3.8 -4.2 kg were used. The right femoral artery was surgically exposed and a 5-F sheath was inserted. Under fluoroscopic guidance, an aseptically prepared channeled stent with microspheres was deployed in the infrarenal aorta. All stents were dilated to a final lumen size of 125% of baseline. All animals (regardless of group) underwent anticoagulation during the procedure and all animals had baseline, postprocedural, and preclosing arteriograms recorded as detailed previously (21) . Animals were fed a 0.25% cholesterol diet after stent implantation.
The stent-implanted portions of the aortae was harvested at 7 days (n ϭ 3 animals per group) and 28 days (n ϭ 3 animals per group) after implantation with use of standard whole-body perfusion fixation technique. The 7-day aortic specimens were excised longitudinally and the stents were removed, whereas, for the 28-day specimens, the stent-implanted aortas with stents in site were embedded in plastic (PolyBed; Polyscience, Warrington, PA). Each stent was divided into even segments to ensure that each region of the stent was represented in the final statistics (ie, to avoid biases that may occur from selecting one particular region such as the end of the stent vs midstent) as previously described (21) .
Evaluation of In Vivo Elastase Inhibition
Residual elastase activity of the aortic samples was assessed to evaluate the inhibitory effect of elastase by stent-based AAT delivery with use of the 7-day specimens (n ϭ 3 for both groups). Stent-implanted segments were mechanically disrupted and solubilized, and aliquots were incubated with 0.1 U elastases (Calbiochem, La Jolla, CA) for 15 minutes at 4°C. Buffer control containing no vessel tissue but phosphate-buffered saline solution was also incubated with the same amount of elastase. Then, a chromogenic assay for elastase activity was performed on all samples with use of colorimetric elastase substrate type I (Calbiochem) and a microplate reader at 450 nm as previously described (22) . Results were expressed as percent change from the buffer control.
Evaluation of Elastin Content
To confirm elastin preservation resulting from elastase inhibition, elastin content in the 7-day aortic specimens (n ϭ 3 animals per group) was measured. Three 5-m-thick cross-sections of the aortic wall were obtained from the paraffin-embedded specimen for each animal, and Verhoeff elastica/ Masson trichrome double staining was employed for these sections. High-resolution images of each section at 100ϫ magnification were obtained with a SPOT true-color digital camera (Diagnostic Instruments, Sterling Heights, MI). With use of ImagePro Plus analysis software (Media Cybernetics, Silver Spring, MD), elastin content in each section was determined by a blinded observer with red channel extraction and thresholding and expressed as a percentage of positive pixels.
Evaluation of Intima/Media Ratio
For 7-day specimens (n ϭ 3 animals per group), three cross-sectional images of the aortic wall with Verhoeff elastica/Masson trichrome double staining were obtained for each animal. An intima-to-media (I/M) ratio for each cross-section was determined from the appropriate area measurements with ImagePro Plus software.
For 28-day specimens (n ϭ 3 animals per group), plastic-embedded samples of stent-implanted aortae were cut into pieces with use of a steel slitting saw to obtain five cross-sectional images at approximately 3-mm intervals. After polishing of the cut surface, these plastic pieces were stained with a Verhoeff elastic stain kit (American Master*tech Scientific, Lodi, CA) with each staining step prolonged to insure adequate penetration of stain agents into the plastic and onto the superficial surface of the embedded tissue (23) . Finally, the I/M ratio was determined as described earlier.
Statistical Analysis
All data are expressed as means Ϯ SE. Statistical significance for all comparisons was determined with use of one-factor repeated-measures analysis of variance and Fisher protected least significant difference post-hoc testing. Statistical significance was defined at a level of P Ͻ .05.
RESULTS
In Vitro Drug Release
The in vitro assay showed the initial bolus of AAT release (mean, 389 ng/mL per 24 hours) from 1 mg of AAT microspheres in the first 24 hours, followed by continuous release (Fig 3) .
In Vivo Elastase Inhibition
Residual elastase activity in treated vessels was measured at 7 days to evaluate whether AAT delivery from microspheres was sufficient to inhibit local elastase activity. Data are expressed as percent decrease from buffer control and values represent means Ϯ SE. Elastase activity measured by percentage in the control group (n ϭ 3) was a 6.1% Ϯ 4.2% decrease, whereas that in the AAT group (n ϭ 3) was a 15.2% Ϯ 3.6% decrease. Local AAT delivery resulted in a 15% decrease of residual elastase activity versus buffer control (P Ͻ .05). There was significant elastase inhibition in the AAT-treated group.
Elastin Content
Elastin content in the 7-day aortic specimens of both groups is shown in Figure 4 as a percentage of positive pixels. A mean value of percentage elastin content in three cross-sections was used for comparison. Elastin content in the AAT group was significantly higher than that in the control group (P Ͻ .05), suggesting that elastin content in the AAT-treated artery was preserved as a result of local elastase inhibition.
Intima/Media Ratio
To evaluate overall efficacy in limiting in-stent neointimal formation, I/M ratios in the stent-implanted aortae were determined at 7 and 28 days. A mean I/M ratio for each animal was used for comparison. As shown in Figure 5 , the I/M ratio in the AAT group was significantly lower than that in the control group at 7 days (0.13 Ϯ 0.01 vs 0.24 Ϯ 0.03; P ϭ .024) and 28 days (1.32 Ϯ 0.10 vs 1.98 Ϯ 0.15; P ϭ .022). Representative photomicrographs of control and AAT groups are presented in Figure 6 . Mural inflammation was not noted in any animals. 
DISCUSSION
Stent-based pharmacologic therapy to enhance local drug delivery has emerged as a promising strategy to prevent restenosis. The potential advantages of delivering the required agent locally to the stent-implanted area are that agents can be used that might be toxic when given systemically, and drugs can be given in doses that do not produce adverse effects but do have a high local concentration. This attractive concept has necessitated the development of drug delivery stents.
We have previously developed a hybrid stent consisting of a channeled stent and biodegradable microspheres in which antistenotic agents can be loaded (21) . The advantages of this platform include controlled and sustained release of therapeutic agents from microspheres, with no accelerated inflammatory reaction, thereby allowing appropriate evaluation of individual drug effect.
Recent developments have shown that ECM remodeling plays an important role in plaque progression and functional consequences (24 -26) . It is demonstrated that there is an early increase in proteolytic activity followed by a late ECM accumulation after balloon arterial injury in animal models, and it is suggested that increased proteolytic activity, particularly of elastase, may play an important role in the development of neointimal hyperplasia (16, 27) .
Elastin, an ECM component of the vessel wall, is a critical determinant of SMC activity. In various studies employing elastin-knockout mice (28) , human atherosclerotic plaque specimens (29) , pig models of cardiac transplant arteriopathy (26, 30) , and rabbit balloon injury models of restenosis (25) , increased endogenous elastase activity and decreased elastin content within the vessel wall have been associated with increased intimal thickening. Consistent with these roles, elastin regulates SMC migration via several mechanisms. Peptides derived from degraded elastin are directly chemotactic to SMCs (31) . In addition, SMC detachment from elastin fibers is promoted when the 67-kd elastinbinding protein on the cell surface is "shed" in the presence of galactosugar-containing ECM elements (eg, chondroitin sulfate) (15, 32) . Production of fibronectin, an ECM element critical to SMC migration, also increases in the vessel wall after elastinbinding protein shedding (33) .
Normal ECM provides a primary functional and architectural barrier to the SMC and inflammatory cell migration that, in part, characterize neointima formation. Moreover, several elements of normal ECM have been shown to prevent smooth muscle mitogenesis directly, even blunting responses to proliferative stimuli as strong as platelet-derived growth factor (PDGF)-BB (28, 34, 35) . Degraded matrix elements, in turn, actually directly stimulate SMC migration and proliferation under certain conditions (28,34 -36) . Matrix-degrading enzymes such as matrix metalloproteinases and elastase have been implicated in neointima formation, and therapies targeting each of these enzymes have significantly decreased neointima formation after mechanical overdilation injury (8, 37) . In addition, local elastase inhibition by transgene expression of elafin (16) and AAT (22) has been shown to be effective in limiting neointimal hyperplasia in a rabbit model. By taking advantage of our newly developed platform, the effect of stent-based controlled release of the elastase inhibitor was investigated in a rabbit aorta. Here, microsphere degradation was predicted by earlier work from our group and others, then verified by assays of release for functional product. When evaluated by sedimentationbased particle sizing, more than 90% of particles have degraded. More importantly, integration of area under the curve for functional assays confirms that essentially all the functional product that will be released has done so during this time period. To show that any intact AAT was incorporated or released from this polymer system, only the controlled drug material (microspheres), which can be problematic, must be evaluated. The gating effect of the hydrogels, even crosslinked, is not relevant here because we have reported on the development of this platform. As described in our earlier work (21) , the hydrogel does alter moment concentrations, incidentally in our favor, by gating release of the initial bolus. To evaluate release from stent channels would introduce variables in mixing that could alter results erroneously here and are not necessary to address the question being asked in this portion of the experiment. Hence, the polymeric composition in question was assessed directly herein.
Significant in vivo elastase inhibition was subsequently confirmed here in AAT-treated vessels versus controls at 7 days after stent implantation. This reduction in elastase activity was sufficient to afford early and late reduction of in-stent neointima, and plaque progression decreased to 67% relative to controls at 28 days. These results suggest that early suppression of the matrix breakdown by stent-based delivery of elastase inhibitor can attenuate SMC migration and eventually limit neointimal formation.
Many potential agents that could reduce neointimal hyperplasia have been identified. For stent-based drug delivery, dexamethasone (38) , hirudin combined with iloprost (39), and tyrosine kinase inhibitors (40) have been used to prevent in-stent restenosis in animals. In addition, rapamycin-(41-44) and paclitaxel-(44 -48) coated stents are currently undergoing clinical trials. In addition, there have been subsequent trials of successors of sirolimusand paclitaxel-eluting stents (49, 50) . Although initial results for drug-eluting stents seem promising (41-50), potential toxicity and limitation may effect long-term efficacy.
Finding an equivalent effect with use of more physiologic agent will be ideal.
For this study, we employed a widely used rabbit model to facilitate a direct comparison to the body of literature for the number of animals at these time points in this model, and we have presented SE instead of SD to facilitate comparison to our earlier body of work. The 7-day and 28-day studies were conducted and evaluated independently with methodologies for each determined by the purpose of the individual experiment. The purpose in the case of the 28-day specimens was an endpoint analysis. The analysis at 7 days was necessary to evaluate the course of the present study and required, at most, formation fixation, whereas paraffin-embedding was not appropriate for the late evaluation. The 7-day time point is early enough that the stents can be removed without disruption. At later time points, the neointima forms a cover over the stent strut (ie, on the adluminal face) and the stent cannot be removed without disruption. These results parallel findings in our previously published work for controls and correlate well with the literature. In addition, any error arising from disruption of the neointima would tend to minimize the neointima in the most advanced cases-herein it would tend to reduce the mean I/M ratio in the higher I/M ratio group, the control group. Hence, if any error were to occur here, it would minimize the detection of therapeutic benefit. Additionally, as discussed earlier, the 7-day specimens must have the stents removed to process as required for the additional analyses because these are not compatible with plastic embedding. Given the relatively small number of animals employed here, future work will need to expand the understanding of the observations made in this pilot study.
Future work must be done to confirm that these results are not speciesspecific and can translate to larger Plastic-embedded aortae with stents were cut into pieces and underwent Verhoeff elastic staining. Stent struts are completely buried in neointima. Note minimal neointimal hyperplasia in the AAT-treated vessel (b). In contrast, the control (a) shows marked neointimal hyperplasia. I ϭ intima; M ϭ media; A ϭ adventitia; S ϭ stent. models. Ultimately, clinical relevance and human models must be confirmed as well. Finally, these strategies follow distinct physiologic pathways, and the potential to combine them with other approaches to achieve added benefits should be examined.
In summary, stent-based controlled release of elastase inhibitor significantly reduces in-stent intimal hyperplasia. This pilot study demonstrates that alteration of proteolytic balance between elastase and its inhibitor is an important pathobiologic factor in the development of neointimal hyperplasia.
